Seasonal Influenza Prophylactics Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Seasonal Influenza Prophylactics Marketed and Pipeline Drugs Report Overview
Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses designated as influenza types A, B, and C. These three types are members of the Orthomyxoviridae family and are structurally related.
The Seasonal Influenza Prophylactics marketed, and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR), and Likelihood of Approval (LoA) for Seasonal Influenza Prophylactics (SIP).
Leading Marketed Vaccines in Influenza
A few of the leading marketed vaccines in influenza market are Fluzone QIV HD, Fluarix Quadrivalent, and Afluria QIV among others. The seasonal influenza vaccine market is dominated by highly competitive players and products of relatively similar efficacy and safety. Due to the complexity of vaccine manufacturing, generics are not available in the influenza vaccine market. This protective environment has limited the 16MM to large pharmaceutical firms such as Sanofi, GSK, Seqirus, Mylan, and AstraZeneca.
Top Sponsors in the Seasonal Influenza Prophylactics Marketed and Pipeline Drugs Market
A few of the top sponsors in the Seasonal Influenza Prophylactics marketed and pipeline drugs market are The National Institute of Allergy and Infectious Diseases, Moderna Inc, GSK plc, Stanford University, Sinovac Biotech Ltd, Seqirus Ltd, Novavax Inc, Vaxart Inc, Novartis AG, and Sanofi.
Seasonal Influenza Prophylactics Marketed and Pipeline Drugs Sponsors Analysis
Buy the full Report for More Sponsor Insights into the Seasonal Influenza Prophylactics Marketed and Pipeline Drugs, Download a Free Report Sample
Seasonal Influenza Prophylactics Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for Seasonal Influenza Prophylactics marketed drugs are injection and inhalational. Most marketed vaccines for influenza are injectable products.
Seasonal Influenza Prophylactics Marketed Drugs Analysis, by Routes of Administration
Buy the full Report for More RoA Insights into the Seasonal Influenza Prophylactics Marketed Drugs, Download a Free Report Sample
Seasonal Influenza Prophylactics Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for Seasonal Influenza Prophylactics pipeline drugs are oral, injection, topical, and inhalational. Of all the influenza pipeline vaccines, injection is the most common route of administration.
Seasonal Influenza Prophylactics Pipeline Drugs Analysis, by Routes of Administration
Buy the full Report for More RoA Insights into the Seasonal Influenza Prophylactics Pipeline Drugs, Download a Free Report Sample
Seasonal Influenza Prophylactics Marketed and Pipeline Drugs – Deals Landscape
- On 1st Nov 2022, Seqirus (CSL Seqirus) Enters into Licensing Agreement with Arcturus Therapeutics
- On 12th Oct 2022, Emergex Vaccines Acquires Zosano Pharma
Buy the full Report for More Deal Insights into the Seasonal Influenza Prophylactics Marketed and Pipeline Drugs, Download a Free Report Sample
Key Molecule Type (Marketed) | · Biologic |
Key Routes of Administration (Marketed) | · Injection
· Inhalational |
Key Routes of Administration (Pipeline) | · Oral
· Injection · Topical · Inhalational |
Top Sponsors (Marketed and Pipeline Drugs) | · The National Institute of Allergy and Infectious Diseases
· Moderna Inc · GSK plc · Stanford University · Sinovac Biotech Ltd · Seqirus Ltd · Novavax Inc · Vaxart Inc · Novartis AG · Sanofi |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Segments Covered in the Report
Seasonal Influenza Prophylactics Marketed Drugs Market Molecule Types Outlook (Number of Products)
- Biologic
Seasonal Influenza Prophylactics Marketed Drugs Market Routes of Administration Outlook (Number of Products)
- Injection
- Inhalational
Seasonal Influenza Prophylactics Pipeline Drugs Market Routes of Administration Outlook (Number of Products)
- Oral
- Injection
- Topical
- Inhalational
Scope
GlobalData’s Seasonal Influenza Prophylactics Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Influenza Prophylactics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Influenza Prophylactics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What is the key molecule type for Seasonal Influenza Prophylactics marketed drugs?
The molecule type in the Seasonal Influenza Prophylactics marketed drugs is biologic.
-
What are the key routes of administration for Seasonal Influenza Prophylactics marketed drugs?
The key routes of administration in the Seasonal Influenza Prophylactics marketed drugs are injection and inhalational.
-
What are the key routes of administration for Seasonal Influenza Prophylactics pipeline drugs?
The key routes of administration in the Seasonal Influenza Prophylactics pipeline drugs are oral, injection, topical, and inhalational.
-
Who are the top sponsors for Seasonal Influenza Prophylactics marketed and pipeline drugs market?
The top sponsors in the Seasonal Influenza Prophylactics marketed and pipeline drugs market are The National Institute of Allergy and Infectious Diseases, Moderna Inc, GSK plc, Stanford University, Sinovac Biotech Ltd, Seqirus Ltd, Novavax Inc, Vaxart Inc, Novartis AG, and Sanofi.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.